• Anuj Sharedalal
    0
    Facility Overview
     Commissioned in Sep 2018, the manufacturing facility is located in RIICO Industrial Area, Keshwana, Rajasthan, India. The facility was set up with a capex of USD 10 million.
     Facility is approved by local FDA authority
     The facility has oral solid dosage (tablets, capsules, dry syrup) and ointment facility, with a scope to set up injectables and eye drop section for general category
     Therapeutic segments: Antihistamine, Antiretroviral, Antiulcer, Antispasmodic, Gastroenterology, Cardiovascular, Antifungal, Analgesics, Antibiotics and Genito Urinary System
     Exports contribute more than 75% of the revenue, with Antiretroviral products and molecules in cephalosporin and macrolides group of antibiotics mainly contributing to company’s exports
     Revenue from operations in FY19 was USD 4 million, with ~49% gross margins. At peak, revenues stood at USD 7 million in FY16
bold
italic
underline
strike
code
quote
ulist
image
url
mention
reveal
youtube
tweet
Add a Comment

Welcome to the MGI M&A Marketplace!

This forum is a marketplace for members of the leading accountancy and legal network and association MGI Worldwide and CPAAI to post Merger and Acquisition opportunities for and from their clients. Participate!